WOLF HALDENSTEIN ENDOLOGIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the Central District of California on behalf of purchasers of Endologix Inc.

NEW YORK, Jan. 25, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP   announces that a  class action lawsuit has been commenced in the United States District Court for  the Central District  of California  on  behalf of  purchasers of  Endologix  Inc.  (Nasdaq:ELGX) (“Endologix”  or the  “Company”)  securities during  the  period between August  2,  2016 through  November  16, 2016,  inclusive  (the  “Class Period”).  

Investors who have incurred losses in Endologix, Inc, shares are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may also review the filed complaint and obtain additional information concerning the action on our website, www.whafh.com.

If  you  purchased  shares of  Endologix  Inc. within the class period and would like to become involved  in assisting the litigation process, you may, no later than March 6, 2017, request that the Court appoint you lead plaintiff of the proposed class.

The filed Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Endologix did not have the necessary clinical data for FDA premarket approval of its Nellix® EndoVascular Aneurysm Sealing System; and (2) consequently, the Company’s public statements were materially false and misleading at all relevant times.

On November 16, 2016, Endologix revealed that the FDA requested the Company to provide them with follow up data for two years for patients enrolled in the EVAS-FORWARD-IDE study to assess Nellix. Following this news, Endologix stock dropped $2.02 per share or over 20% to close at $7.82 per share on November 16, 2016.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact  Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

Follow the firm and learn about newly filed cases on Twitter and Facebook. 

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP 
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4708